Search

Posterior uveitis, or choroiditis, refers to inflammation of the choroid. It can affect the retina and/or optic nerve and lead to permanent loss of vision. What causes posterior uveitis? Posterior uveitis can be infectious or non-infectious. Many non-infectious cases are idiopathic. Common non...

Checkpoint inhibitors are becoming more widely used in the management of cancer, so it is important for the ophthalmologist to examine the medication list carefully in a patient with new-onset uveitis. Uveitis Associated with Immune Checkpoint Inhibitors Immune checkpoint inhibitors are used...

DOWNLOAD FULL ISSUE Education, Research, and Reflection Provide Strong Foundations for Unrivaled Clinical Care In this final installment of our 2020 Vision series, you will read about Harvard Ophthalmology’s 20 years of groundbreaking advances and how they helped to define clinical excellence...

DOWNLOAD FULL ISSUE Inclusion, Diversity, and Equity at Harvard Ophthalmology In the latest issue of Eye Witness, we highlight our latest efforts on inclusion, diversity, and equity, including our EYE CAN program, a multi-tiered framework created by our IDE leaders that aims to increase diversity...

Dear Colleagues, In this issue of eye Insights, we take a close look at posterior uveitis. Inside, you’ll find techniques and tips for evaluating and managing patients with this condition. Due to its many etiologies, posterior uveitis can be challenging to treat until the cause of the inflammation...

The most common symptoms of posterior uveitis are blurred vision and floaters, and the most common signs are chorioretinal infiltrates and vitreous cells. Posterior uveitis is diagnosed by slit lamp examination and indirect ophthalmoscopy. Imaging modalities, including fundus autofluorescence...

While gene therapy is not yet widely available for inherited retinal disorsers (IRDs), researchers are making exciting discoveries, and the future looks more promising than ever before. In this issue of eye Insights, we provide a look into current offerings in gene therapy, and a glimpse into the...

Inherited retinal disorders are rare, hereditary disorders caused by mutations in genes that encode proteins needed for normal retinal health and function. The first gene associated with retinitis pigmentosa was identified at Mass Eye and Ear in 1990, and since then, over 250 IRD-causing genes have...

The first gene-augmentation therapy for an IRD was approved by the U.S. Food and Drug Administration (FDA) in December 2017 after nearly two decades of development in preclinical models and clinical trials. The drug, known as Luxturna®, is for individuals with autosomal recessive retinal dystrophies...

Dear Colleagues, Research in gene augmentation and genome editing for the treatment of inherited retinal disorders (IRDs) is thriving. It is estimated that IRDs affect about 200,000- 300,000 people in the United States and 4-6 million people worldwide. Most patients with these conditions become...